c-Met/HGFR

c-Met, also called tyrosine-protein kinase Met or hepatocyte growth factor receptor (HGFR), is a protein that in humans is encoded by the MET gene. The protein possesses tyrosine kinase activity. The primary single chain precursor protein is post-translationally cleaved to produce the alpha and beta subunits, which are disulfide linked to form the mature receptor.MET is a single pass tyrosine kinase receptor essential for embryonic development, organogenesis and wound healing.

Cat. No.	Product name	CAS No.	Purity
T63313	Unecritinib	1418026-92-2	98%
T63313	Unecritinib (TQ-B3101) is a potent, orally active, highly potent, blood-brain barrier permeable and low toxic inhibitor of EGFR tyrosine kinase with antitumor ac...
T77437	Telisotuzumab	1781223-80-0	98%
T77437	Telisotuzumab(ABT-700) is a humanized recombinant antibody targeting the therapeutic hepatocyte growth factor receptor (MET) with high affinity for c-Met.Telisot...
T3512	S49076 HCl	1265966-31-1	98%
T3512	S49076 is an effective inhibitor of MET, AXL/MER, and FGFR1/2/3. S49076 potently blocked cellular phosphorylation of MET, AXL, and FGFRs and inhibited downstream...
T12417	PF-04217903 methanesulfonate	956906-93-7	98%
T12417	PF-04217903 methanesulfonate is a potent ATP-competitive inhibitor of c-Met kinase (Ki of 4.8 nM for human c-Met).
T10653	C-met-IN-1	2084836-84-8	98%
T10653	c-met-IN-1 is a potent and selective c-Met inhibitor (IC50: 1.1 nM) with antitumor activity.
T17184	Tyrosine kinase inhibitor	1021950-26-4	98%
T17184	Tyrosine kinase inhibitor is a tyrosine kinase inhibitor used in combination with fragmenting aromatic nitrogen compounds as antiproliferative agents.
T15383	Glesatinib hydrochloride	1123838-51-6	98%
T15383	Glesatinib hydrochloride is an orally active and potent dual inhibitor of MET/SMO. Glesatinib hydrochloride is also a tyrosine kinase inhibitor. It antagonizes P...
T10654	C-Met-IN-2	1635406-73-3	98%
T10654	c-Met-IN-2 is a selective and orally available c-Met inhibitor (IC50: 0.6 nM) with antitumor activity.
T12418	PF-04217903 phenolsulfonate	1159490-85-3	98%
T12418	PF-04217903 phenolsulfonate is a potent ATP-competitive inhibitor of c-Met kinase (Ki of 4.8 nM for human c-Met).
T15384	Glesatinib	936694-12-1	98%
T15384	Glesatinib is an orally active and potent dual inhibitor of MET/SMO. Glesatinib is also a tyrosine kinase inhibitor. It antagonizes P-glycoprotein mediated multi...
TN4474	Macrocarpal B	142698-60-0	98%
TN4474	The intestinal absorption of M-A, Macrocarpal B, and Cy-C was passive diffusion as the dominating process and Cy-C was partly ATP-dependent.
T6117	Tivantinib	905854-02-6	98%
T6117	Tivantinib is an orally bioavailable small molecule inhibitor of c-Met with potential antineoplastic activity.
T2894	Norcantharidin	5442-12-6	98%
T2894	Norcantharidin is a synthetic anticancer compound which is a dual inhibitor for c-Met and EGFR in human colon cancers.
T8825	Capmatinib 2HCl.H2O	1865733-40-9	98%
T8825	Capmatinib 2HCl.H2O is an orally bioavailable inhibitor of the proto-oncogene c-Met (HGFR)with potential antineoplastic activity.
T25492	Hepln-13	64369-13-7	98%
T25492	Hepln-13 is a hepsin inhibitor that acts by hindering prostate cancer bone metastasis.
T5349	SCR-1481B1	1174161-86-4	98%
T5349	SCR-1481B1 has activity against cancers dependent on Met activation and also has activity against cancers as a VEGFR inhibitor
T3209	AMG-337	1173699-31-4	98%
T3209	AMG-337 is an effective and highly specific ATP-competitive MET kinase inhibitor. In enzymatic assays, AMG-337 inhibits MET kinase activity (IC50: < 5 nM).
T2419	BMS-794833	1174046-72-0	98%
T2419	BMS-794833 is a potent ATP competitive inhibitor of Met/VEGFR2; a prodrug of BMS-817378.
TQ0041	Ningetinib Tosylate	1394820-77-9	98%
TQ0041	Ningetinib Tosylate is an orally bioavailable tyrosine kinase inhibitor with IC50s of <1.0, 1.9 and 6.7 nM for Axl, VEGFR2, and c-Met, respectively.
T1963	Capmatinib	1029712-80-8	98%
T1963	Capmatinib is an orally bioavailable inhibitor of the proto-oncogene c-Met (HGFR)with potential antineoplastic activity.